Nanomedicine based potentially transformative strategies for colon targeting of peptides: State-of-the-art

• Published in: Colloids and surfaces, B, Biointerfaces Vol. 219; p. 112816
• Main Authors: Vambhurkar, Ganesh, Amulya, Etikala, Sikder, Anupama, Shah, Saurabh, Famta, Paras, Khatri, Dharmendra Kumar, Singh, Shashi Bala, Srivastava, Saurabh
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.11.2022
• Subjects: Barriers; Colon-specific delivery; Nanocarriers; Peptides; Regulatory perspectives; PS; STC; Peptides; DL; AUC; BSA; SDC; BAs; EMA; Nanocarriers; EE; PBS; DSS; sCT; SMA; NDAs; Regulatory perspectives; CHs; GIT; ZP; SEM; FD&C; PCM; ANDA’s; ELISA; FDA; Colon-specific delivery; DMEC; DLS; IBD; mRNA; RLD; CPPs; INS; CDER; ACHs; PDI; SLNs; IBS; GG; GLP-1; PMB; OACS; SZ; TMC; EDTA; SSM; HPMCP; SGC; ICH; NPs; BLPs; PEG; PLGA; TEC; Barriers; SCFAs; API; PVA; VIP; TEM
• ISSN: 0927-7765; 1873-4367
• DOI: 10.1016/j.colsurfb.2022.112816

Recently, peptides have attracted tremendous attention among researchers attributed to their high target specificity and efficacy compared to conventional therapeutics. The ease of self-administration and non-invasiveness confers oral as the most desirable route. However, numerous challenges associated with peptide delivery through the oral route like harsh gastrointestinal environment, enzymatic degradation, and absorption barriers hinder its clinical translation. Protease activity is more pronounced in the proximal segments of the gastrointestinal tract (GIT). Distal segments like the colon possess lower proteolytic activity, enhanced retention time, etc. which could facilitate easy absorption. However, traversing of the upper segments to reach the colon requires the circumvention of the pitfalls of the GIT. The advent of nanomedicine strategies could help in overcoming the said challenges associated with oral delivery, colon-specific targeting, and improving stability and bioavailability at the active site. Furthermore, the classification of peptides and various nanomedicine strategies for oral delivery of peptides to the colon has been conveyed. Regulatory hurdles and ways to accomplish clinical translation have been addressed. [Display omitted] •Prevalence and classification of oral colonic peptides have been conveyed.•Nanomedicine strategies could help in circumventing oral peptide delivery to colon.•Nanocarriers for oral colonic peptide delivery have been described.•Regulatory considerations for hastening clinical translation have been revealed.